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1. 1. The research object
Life quality of patients with ovarian cancer after complex treatment 
1. 2. Description of the problem.
Ovarian cancer remains a complicated medical issue. According to worldwide statistics, 
1-year, 3-year and 5-year survival rates are 63 %, 41 %, 35 %, respectively [1]. In the last decade a 
modest decrease of 5-year survival was caused by more common use of platinum-based chemother-
apy for disseminated ovarian cancer [2].
More than 70 % cases of ovarian cancer are revealed at late stages, that accounts for poor 
prognosis. Contemporary treatment standards include combination of surgical cytoreduction and 
platinum-based chemotherapy. However, even after complete cytoreduction with adjuvant first-line 
systemic treatment, that achieved complete clinical regression, 5-year survival rates for III and IV 
stages are 20 % and 10 %, respectively [3]. 
1. 3. Suggested way to solve the problem 
Most patients respond well to first-line therapy, although 30 % may have a platinum-resis-
tant or platinum-refractory tumors. In such cases other cytostatic drug combinations, target thera-
A B S T R A C T
The research object was life quality of patients with ovarian cancer after complex 
treatment. Nowadays cytoreductive surgery and HIPEC is the mainstay of manage-
ment of advanced stages ovarian cancer. 
Description of the problem: study was conducted to assess the effectiveness of com-
bined treatment in IIIA-IIIC ovarian cancer, its impact on quality of life. 
Main scientific results: 37 patients of main group (CRS + HIPEC) were compared 
with 25 patients of control group (surgery + systemic chemotherapy). The quality of 
life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey 
(SF-36). Comparative analysis of quality of life 6 months after treatment completion 
did not show significant statistical difference. Combination of cytoreduction with 
HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and 
has less systemic toxicities than systemic chemotherapy.
The area of practical use of research results: hyperthermic intraperitoneal chemo-
therapy is performed for patients suffering from malignant tumors of the abdominal 
cavity, including metastatic colon cancer, ovarian cancer, stomach cancer, pseudomyx-
oma, mesothelioma, rhabdomyosarcoma, and some other types of oncology.
Innovative technological product: combination of cytoreduction with HIPEC im-
proves quality of life in patients with ovarian cancer.
Scope of application of an innovative technological product: HIPEC is an inno-
vative treatment option for advanced cancer that has spread to the abdominal cavity 
(carcinomatosis) and has not gone beyond it.
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py and immunotherapy is recommended [4]. To sum up, despite absence of clinical signs, one third 
of patients after first-line chemotherapy will have relapse in 2–3 years. Objective response rate is 
10–25 %, median survival time is 7–18 months [5]. Most studies share an opinion, that optimal 
cytoreduction is crucial for effective treatment. However, only 10–15 % of performed surgeries 
achieve optimal extent. That is why it is still relevant to improve methods of surgical and adjuvant 
methods of ovarian cancer treatment [6]. 
The aim of the research. The study was conducted to assess the effectiveness of cytore-
ductive surgery in combination with hyperthermic intraperitoneal chemoperfusion (HIPEC) in 
advanced stages of ovarian cancer management. The article displays the experience of University 
clinic of Odessa National Medical University. 
2. Materials and methods
37 cases of ovarian cancer treated with cytoreduction, HIPEC and 4–6 courses of adjuvant 
chemotherapy were analyzed. Study has been conducted in the Department of Surgery No. 4 with 
the Course of Oncology (Odessa National Medical University) since 2016 and is continued now. 
All patients had serosal papillary ovarian cancer FIGO IIIA-IIIC. Patients age was 31–59 years, 
the middle age was 43±7 years old. Control group included 25 patients after surgical treatment and 
convenient systemic chemotherapy. All patients received suboptimal cytoreduction.
Before including patients in the study protocol, personal written voluntary consents were 
obtained to participate in the study in accordance with the Helsinki Declaration of the World Med-
ical Association (protocol No. 119А bioethics commission meetings of Odessa National Medical 
University, 15.05.2016)
Criteria of exclusion were age more than 70 years, extensive canceromatosis with peritone-
al canceromatosis index more than 20, unresectable small bowel involvement, distant metastasis, 
retroperitoneal lymphadenopathy, unresectable retroperitoneum invasion, severe concomitant pa-
thology. Previous surgeries with massive adhesions were considered as relative contraindication.
Cytoreduction included visceral resections and peritonectomy. Hysterectomy with bilateral 
adnexectomy, omentectomy and selective parietal peritonectomy was performed.
HIPEC is performed in the University clinic of Odessa National Medical University with 
Performer LRT (Rand, Italy). Its main components are two pumps, heater, infusion lines and digital 
integrational system. The apparatus controls the procedure automatically and allows fine tuning 
and monitoring of different parameters like temperature, volume speed, target volumes and timing.
All patients in the main group received HIPEC with cisplatine and doxorubicine. Drugs 
are dissolved in 5000–6000 ml of isotonic perfusate. Сlosed technique was used, that is after 
wound closure 5–6 silicone drains are placed into abdominal and pelvic cavity. Procedures lasted 
60–90 minutes with target intraperitoneal temperature 40–41 °C and volume speed 800–900 ml/min. 
Mean filling volume is 2500–3000 ml depending of patients constitution. The washout phase takes 
10–15 minutes until clear outflow and normothermia is achieved.
All patients received cytoprotection with thiosulfate during HIPEC and 6 hours after to 
prevent systemic toxicity of cisplatine. Usually patients stayed for one day in the intensive care 
unit. Perioperative medications include dexamethasone, 5-HT blockers, adequate analgesics and 
infusional therapy. Antibiotic prophylaxis was protracted for 1–3 days if needed.
Patients were assessed intraoperatively according to peritoneal canceromatosis index, pre-
vious surgical score, cytoreduction completeness score. The quality of life was analyzed with Med-
ical Outcomes Study 36-Item Short Form Health Survey (SF-36). Adverse effects and toxicities 
were secondary outcomes of the study. Time series statistics were used to analyze the obtained 
data. To assess the significance of these changes, was used the Mann-Whitney parametric test. 
SPSS Statistics was used as software for estimating statistics.
3. Results
Among the main group (n=37) IIIA, IIIB, IIIC stages were revealed in 5, 3 and 29 patients, 
respectively. In the control group (n=25), 10 patients had IIIA, 2 patients – IIIB, 13 patients – IIIC. Can-
ceromatosis index in the main group was LS-1 (28.0 %) and LS-2 (72.0 %). It did not differ significantly 
in control group: LS-1 – 36.0 %, LS-2 – 64.0 %. Cytoreduction completeness score had no statistical 
difference (CC-1 and CC-2 was 28.0 %, 72.0 % in main group, 36.0 %, 64.0 % in control group).
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Comparative analysis of quality of life 6 months after treatment completion did not showed 
nonsignificant statistical difference (Table 1).
Table 1
Comparison of the Short Form (36) Health Survey
SF-36 Scale Main group (n=37) Control group (n=25)
Physical activity 34.08±21.14 31.88±19.44
Physical role functioning 28.42±13.43 21.01±14.23
Bodily pain 46.29±16.23 41.27±20.11
General health perceptions 35.33±14.76 33.72±23.27
Vitality 49.85±24.16 44.25±34.26
Social role functioning 65.42±26.16 63.12±22.39
Emotional role functioning 42.11±15.46 44.25±17.24
Mental health 66.32±22.26 59.32±22.26
No allergic and idiosyncratic drug reactions were observed in the main group. 9 patients had 
temporary hyperthermic reaction, controlled with NSAIDs.
Few patients (n=5, 13.5 %) complained about pain around drain contrapertures.
Toxicities comparison of treatment regimens is shown in the Tables 2, 3.
Table 2




I, n (%) II, n (%) III, n (%) IV, n (%)
Leukopenia 13 (35.1) 7 (18.8) 4 (10.8) 3 (8.1) 72.8
Neutropenia 12 (32.4) 6 (16.2) 5 (13.5) – 62.1
Anemia 3 (8.1) 2 (5.4) – – 13.5
Thrombocytopenia 6 (16.2) – – – 16.2
Nausea 7 (18.9) 5 (13.5) 5 (13.5) – 45.9
Vomiting 16 (43.2) 1 (2.7) 1 (2.7) – 48.6
Diarrhea 3 (8.1) – – – 8.1
Stomatitis 8 (21.6) 1 (2.7) – – 24.3
Table 3




I, n (%) II, n (%) III, n (%) IV, n (%)
Leukopenia 10 (40.0) 8 (32.0) 1 (4.0) 1 (4.0) 80.0
Neutropenia 11 (44.0) 4 (16.0) 2 (8.0) 1 (4.0) 72.0
Anemia 5 (20.0) 4 (16.0) 4 (16.0) – 52.0
Thrombocytopenia 4 (16.0) – – – 8.0
Nausea 7 (28.0) 4 (16.0) 4 (16.0) – 60.0
Vomiting 10 (40.0) 4 (16.0) 1 (4.0) – 60.0
Diarrhea 3 (12.0) – – – 12.0
Stomatitis 2 (8.0) 4 (16.0) 1 (4.0) – 28.0
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Hematological, gastrointestinal adverse effects were comparable in both groups. Less neph-
rotoxicity was observed in the control group.
Mean hospital stay was 8.9 days in the main group and did not differ significantly from 
control group.
4. Discussion
Cytoreduction and HIPEC have a reasonable rationale. Several tumors (ovarian cancer, ma-
lignant mesothelioma, colorectal and gastric cancer), that evolve into peritoneal carcinomatosis, 
in some stages of development are locally contained within serosal lining without giving distant 
metastases [7, 8]. Macroscopic tumor removal with surgical cytoreduction and microscopic with 
HIPEC achieves locoregional control.
By definition, chemotherapeutic drugs have various grades of systemic toxicities. Their 
use in high concentrations may cause serious adverse effects. Regional chemotherapy can 
achieve high local concentrations without systemic leakage into systemic circulation. Hyper-
thermia has direct selective cytotoxicity and acts synergistically with alkylating agents, like 
anthracyclines [9, 10]. In addition, it improves drug penetration into tumor deposits. Con-
tinuous cavity chemoperfusion supports constant chemotherapeutic agents concentration and 
equal distribution. These features explain better “local” intraperitoneal control after HIPEC 
comparing to systemic chemotherapy.
Study limitations. The study was carried out on the basis of one clinic, the study was not 
placebo-controlled, the patients were not divided into groups according to BRCA.
The research is continued now and the new results will be published as soon as possible.
5. Conclusions
1. Combination of cytoreduction with HIPEC provides significant prolongation of life for 
patients with advanced ovarium cancer and increases their life quality.
2. HIPEC is proven to be effective in conjunction with optimal or suboptimal cytoreduction.
3. HIPEC is tolerated better and has less systemic toxicities in comparison with systemic 
chemotherapy. Minimizes harm to other organs outside the abdominal cavity. Reduces some of the 
side effects of systemic chemotherapy.
4. Unlike systemic chemotherapy, which enters the body through the circulatory system 
and circulates throughout the body, in the HIPEC procedure, the chemotherapy drug acts directly 
on cancer cells that have spread in the abdominal cavity. This allows for high-dose chemotherapy 
treatments. Heating the chemotherapeutic method allows to improve the degree of absorption of 
drugs by tumor cells and to achieve an effect on malignant cells remaining in the abdominal cavity 
after surgical resection of visible tumor foci.
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